Active	Status	Sponsor type	Region	Phase	Filter
1 Active 1 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Zeyzelf (rivastigmine twice weekly) / Luye Group
NCT05853341: Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (13.3mg/24h)	Completed	1	48	Europe	RID-TDS 13.3 mg/24 h, Exelon® 13.3 mg/24 h	Luye Pharma Group Ltd., SocraTec R&D GmbH, SocraMetrics GmbH	Healthy	07/23	07/23